A Randomized, Open-Label, Two-way Crossover Bioequivalence Study of Cilacar Tablet Compared with Atelec Tablet in Healthy Volunteers Under Fasting Condition
Cilnidipine is a novel L/N type calcium channel blocker, approved in several countries world-wide for the treatment of hypertension and is also well-established for its varied pleiotropic benefits. Cilnidipine was first approved in India in 2007, for the treatment of mild to moderate hypertension and since then has been a widely trusted and prescribed molecule. We conducted an open label, analyst blind, randomized, two-treatment, two-period, two sequence, single dose, crossover study to assess and compare the bioequivalence of test product Cilacar 10 mg and 20 mg tablet with reference product Atelec® 10 mg and 20 mg tablet, respectively in healthy volunteers. Blood samples were collected pre-dose and at regular intervals post-dose up to 24 hours. Plasma drug levels were determined with a validated chromatographic method. Pharmacokinetic parameter (Cmax), (AUC0–t), (AUC0–∞), (Tmax), (T½) and (Kel) was calculated. The 90% confidence intervals on the mean of difference between Cilacar 10 mg and Atelec® 10 mg were 82.61% to 121.80%, 88.35% to 109.72%, and 87.54% to 110.52% and The 90% confidence intervals on the mean of difference between Cilacar 20 mg and Atelec® 20 mg were 89.65% to 116.08%, 88.09% to 111.30%, and 88.35% to 110.79% for Cmax, AUC (0-t) and AUC (0–∞) respectively. All the volunteers completed the study. It can be concluded from the results, the test product Cilacar 10 mg and 20 mg and the reference product Atelec® 10 mg and 20 mg tablet met the required bioequivalence criteria. Both products were safe and well tolerated.
Keywords Bioequivalence, Cilnidipine, Calcium channel blocker, Hypertension, and Blood pressure
2. Anupama, Y. J., et al. "Hypertension is an important risk determinant for chronic kidney disease: results from a cross-sectional, observational study from a rural population in South India." Journal of human hypertension 2017; 31(5):327-332. https://doi.org/10.1038/jhh.2016.81
3. Abraham G, Arun KN, Gopalakrishnan N, Renuka S, Pahari DK, Deshpande P, Isaacs R, Chafekar DS, Kher V, Almeida AF, Sakhuja V. "Management of hypertension in chronic kidney disease: consensus statement by an expert panel of Indian nephrologists". The Journal of the Association of Physicians of India. 2017; Feb; 65(2 Suppl):6-22. PMID: 28829108
4. Chandra KS, Ramesh G. "The fourth-generation Calcium channel blocker: Cilnidipine". Indian heart journal, 2013; Dec 1; 65(6):691-5. DOI: https://doi.org/10.1016/j.ihj.2013.11.001
5. Lee YJ, Park KH, Park HH, Kim YJ, Lee KY, Kim SH, Koh SH. "Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway". J Neurochem. 2009; Oct; 111(1):90-100. DOI: https://doi.org/10.1111/j.1471-4159.2009.06297.x
6. Takahara A, Konda T, Enomoto A, Kondo N. "Neuroprotective effects of a dual L/N-type Ca2+ channel blocker cilnidipine in the rat focal brain ischemia model". Biological and Pharmaceutical Bulletin. 2004; 27(9):1388-91. DOI: https://doi.org/10.1248/bpb.27.1388
7. Chakraborty RN, Langade D, More S, Revandkar V, Birla A. "Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension": A Meta-Analysis of Randomized and Non-Randomized Controlled Trials. Cureus. 2021; Nov 22; 13(11). DOI: https://doi.org/10.7759/cureus.19822
8. Bhalerao A, Choudhari P, "Formulation of Solid Lipid Nanoparticles of Cilnidipine for the Treatment of Hypertension", Journal of Drug Delivery and Therapeutics. 2019; 9(3):212-221 DOI: https://doi.org/10.22270/jddt.v9i3.2849
9. Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discovery Today. 2013 Dec 1; 18(23-24):1173-84. DOI: https://doi.org/10.1016/j.drudis.2013.08.013
10. Napolean KJ, Darling CD, R Kavitha. "A randomized open label parallel group study comparing the efficacy and safety of cilnidipine and amlodipine in hypertensive adults." Journal of the Association of physicians of India. Dec. 2021. PMID: 35057591
11. Drug Controlled General of India, IST OF APPROVED DRUG, Cilnidipine, Approved Date 21-6-2007, Available at:
http://ctri.nic.in/Clinicaltrials/WriteReadData/dcgi/6168238804Amelaxanox%20approval.pdf accessed on 14-02-2022
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).